STAT3 inhibition as a therapeutic strategy for leukemia

Rubashruti Kanna, Gaurav Choudhary, Nandini Ramachandra, Ulrich G. Steidl, Amit K. Verma, Aditi Shastri

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

Leukemia is characterized by selective overgrowth of malignant hematopoietic stem cells (HSC’s) that interfere with HSC differentiation. Cytoreductive chemotherapy can kill rapidly dividing cancerous cells but cannot eradicate the malignant HSC pool leading to relapses. Leukemic stem cells have several dysregulated pathways and the Janus kinases (JAKs) and signal transducer and activator of transcription (STAT) pathway are prominent among them. STAT3 is an important transcription factor that regulates cell growth, proliferation, and inhibits apoptosis. High STAT3 expression in leukemia has been associated with an increased risk for relapse and decreased overall survival. Multiple strategies for interfering with STAT3 activity in leukemic cells include inhibition of STAT3 phosphorylation, interfering with STAT3 interactions, preventing nuclear transfer, inhibiting transcription and causing interference in STAT: DNA binding. A better understanding of key interactions and upstream mediators of STAT3 activity will help facilitate the development of effective cancer therapies and may result in durable remissions.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalLeukemia and Lymphoma
DOIs
StateAccepted/In press - Nov 23 2017

Keywords

  • Leukemia
  • signal transduction
  • transcription factor changes

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'STAT3 inhibition as a therapeutic strategy for leukemia'. Together they form a unique fingerprint.

  • Cite this